Keratoacanthoma
☆ Katika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa.
Kawaida Keratoacanthoma
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) ni uvimbe wa ngozi unaojitokeza mara kwa mara, unaojulikana kwa ukuaji wake wa haraka na uwezo wa kutokomeza bila matibabu. Mara nyingi hutokea kwa wanaume wazee wenye ngozi nzito na historia ya uharibifu wa jua. Ingawa upasuaji wa kukata au upasuaji wa micrographic wa Mohs ndizo matibabu ya kawaida, kuna njia nyingine nyingi za matibabu zinazopatikana.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ni uvimbe wa kiwango cha chini unaotokana na tezi fulani kwenye ngozi na hufanana na squamous cell carcinoma (SCC) kwa darubini. Kuna mjadala unaoendelea kuhusu kama KA inafaa kuainishwa kama aina ya SCC vambavu.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) ni aina ya pili ya saratani kwa watu, hasa kati ya wazee. Upasuaji kwa kawaida hutumika kutibu cSCC, lakini kwa wagonjwa ambao hawawezi kufanyiwa upasuaji au wanapendelea kuepuka upasuaji, chaguzi nyingine kama matibabu ya ndani ya kidonda zinaweza kuzingatiwa. Matibabu ya kitamaduni ya ndani ya kidonda (methotrexate au 5-fluorouracil) yamekuwa yakitumika, lakini utafiti unaendelea kuhusu mbinu mpya kama tiba ya kinga ya ndani ya kichwa na matibabu ya virusi oncolytic. Hapa, tutaangalia matibabu mbalimbali ya ndani kwa cSCC, kuanzia mbinu za kisasa hadi mikakati ya kisasa.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Kwa darubini, keratoacanthoma inafanana sana na saratani ya seli ya squamous. Ingawa baadhi ya wanapatholojia wanaitwa keratoacanthoma “huluki mahususi” na hawaii kama ugonjwa mbaya, takriban 6 % ya kesi za keratoacanthoma kwa histolojia hubadilika kuwa saratani ya seli ya squamous yenye uwezo wa kuenea.
○ Uchunguzi na Tiba
#Dermoscopy
#Skin biopsy